| ²é¿´: 351 | »Ø¸´: 1 | |||
ÂäÑ©º¬Ïã½ð³æ (ÕýʽдÊÖ)
|
[½»Á÷]
¡¾ÇóÖú¡¿Õâ¾ä»°Ôõô·Ò루ÎÒ²»ÖªµÀ·¢µ½Äĸö°æ¿é£© ÒÑÓÐ1È˲ÎÓë
|
|
Its major drawback is dose-limiting systemic toxicity of the therapeutic agents. ´ó¼Ò°ïÎÒ·Òëһϣ¬µ¥¸ö´ÊÎÒµ¹ÊÇ»á·Ò룬Á¬³ÉÒ»¸öͨ˳µÄ¾ä×Ó¸ÃÊÇÊ²Ã´ÄØ£¿ |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8.O.5.5.1.O.5.4,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ3È˻ظ´
ҩѧÇóµ÷¼Á
ÒѾÓÐ15È˻ظ´
0854Çóµ÷¼Á
ÒѾÓÐ16È˻ظ´
³õÊÔ324 ÖÐҩѧ Ò»Ö¾Ô¸ÌìÖÐÒ½ Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
279ѧ˶ʳƷרҵÇóµ÷¼ÁԺУ
ÒѾÓÐ29È˻ظ´
294Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸Öпƴó²ÄÁÏÓ뻯¹¤£¬353·Ö»¹Óе÷¼ÁѧУÂð
ÒѾÓÐ4È˻ظ´
¿ÒÇëÓÐѧУÊÕÁô
ÒѾÓÐ6È˻ظ´
Çóµ÷¼ÁÍÆ¼ö
ÒѾÓÐ8È˻ظ´
300Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
jxf8257
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 987.1
- É¢½ð: 40
- Ìû×Ó: 495
- ÔÚÏß: 30Сʱ
- ³æºÅ: 660305
- ×¢²á: 2008-11-23
- רҵ: Ò©Îﻯѧ
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
| ¸ÃÖÎÁÆÊÔ¼ÁµÄÖ÷ҪȱµãÊǼÆÁ¿ÏÞÖÆµÄϵͳ¶¾ÐÔ |
2Â¥2010-06-02 18:37:35













»Ø¸´´ËÂ¥
20